Orchestra BioMed Holdings (OBIO) Cost of Revenue (2022 - 2026)
Orchestra BioMed Holdings (OBIO) reported Cost of Revenue of $32000.0 for Q1 2026, down 27.27% year-over-year from $44000.0 in Q1 2025, and down 37.25% on a QoQ basis from $51000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 5 years of Cost of Revenue data on file, last reported at $32000.0 in Q1 2026.
- Quarterly Cost of Revenue fell 27.27% year-over-year to $32000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178000.0 (down 16.82% YoY) and the FY2025 annual result came in at $190000.0, down 6.86% from the prior year.
- Cost of Revenue slipped to $32000.0 in Q1 2026 per OBIO's latest filing, from $51000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $68000.0 in Q3 2024 and bottomed at $32000.0 in Q1 2026.
- The 5-year median for Cost of Revenue is $47000.0 (2023), against an average of $48411.8.
- The widest annual swing landed in 2024, when Cost of Revenue soared 65.85%; it then decreased 27.94% in 2025.
- Tracing OBIO's Cost of Revenue over 5 years: stood at $53000.0 in 2022, then retreated by 11.32% to $47000.0 in 2023, then rose by 23.4% to $58000.0 in 2024, then retreated by 12.07% to $51000.0 in 2025, then tumbled by 37.25% to $32000.0 in 2026.
- Per Business Quant, the three latest OBIO Cost of Revenue figures stand at $32000.0 (Q1 2026), $51000.0 (Q4 2025), and $49000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | 32,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32,000.00 |
| Mar 31, 2026 | 32,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 46,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Sep 30, 2023 | 41,000.00 |
| Sep 30, 2023 | 41,000.00 |
| Jun 30, 2023 | 54,000.00 |
| Jun 30, 2023 | 54,000.00 |
| Mar 31, 2023 | 44,000.00 |
| Mar 31, 2023 | 44,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Sep 30, 2022 | 56,000.00 |
| Sep 30, 2022 | 56,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 42,000.00 |
| Mar 31, 2022 | 42,000.00 |